Clover Wolf Capital – Limited Purchases 178,717 Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited purchased 178,717 shares of the business’s stock in a transaction on Monday, June 8th. The shares were purchased at an average cost of $7.36 per share, for a total transaction of $1,315,357.12. Following the transaction, the insider now owns 2,601,311 shares of the company’s stock, valued at $19,145,648.96. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Thursday, June 18th, Clover Wolf Capital – Limited bought 49,000 shares of Pluristem Therapeutics stock. The stock was bought at an average price of $7.36 per share, for a total transaction of $360,640.00.
  • On Wednesday, June 10th, Clover Wolf Capital – Limited purchased 25,000 shares of Pluristem Therapeutics stock. The stock was acquired at an average price of $6.91 per share, for a total transaction of $172,750.00.
  • On Thursday, June 4th, Clover Wolf Capital – Limited bought 7,610 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.86 per share, for a total transaction of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited bought 117,489 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.57 per share, for a total transaction of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited bought 1,797 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.95 per share, for a total transaction of $14,286.15.
  • On Wednesday, May 27th, Clover Wolf Capital – Limited bought 90,000 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $8.14 per share, for a total transaction of $732,600.00.

Shares of PSTI opened at $8.84 on Wednesday. The company has a market capitalization of $219.17 million, a P/E ratio of -2.68 and a beta of 2.60. Pluristem Therapeutics Inc. has a one year low of $2.82 and a one year high of $13.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.47 and a current ratio of 2.47. The stock has a 50-day moving average price of $8.28 and a 200 day moving average price of $5.75.

A number of institutional investors and hedge funds have recently modified their holdings of PSTI. Jane Street Group LLC boosted its position in shares of Pluristem Therapeutics by 5.9% in the first quarter. Jane Street Group LLC now owns 71,294 shares of the biotechnology company’s stock worth $262,000 after buying an additional 3,945 shares during the period. ETF Managers Group LLC boosted its position in shares of Pluristem Therapeutics by 9.8% in the first quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock worth $206,000 after buying an additional 5,764 shares during the period. Levin Capital Strategies L.P. purchased a new stake in shares of Pluristem Therapeutics during the first quarter worth $37,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Pluristem Therapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock worth $1,077,000 after acquiring an additional 87,188 shares in the last quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the company. Dawson James reissued a “buy” rating on shares of Pluristem Therapeutics in a report on Wednesday, April 15th. HC Wainwright reissued a “buy” rating and issued a $15.50 price target on shares of Pluristem Therapeutics in a report on Thursday, May 14th. Zacks Investment Research cut Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Maxim Group reissued a “buy” rating and issued a $12.00 price target on shares of Pluristem Therapeutics in a report on Friday, May 15th. Finally, Jefferies Financial Group started coverage on Pluristem Therapeutics in a research note on Friday, June 19th. They issued a “buy” rating and a $12.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Pluristem Therapeutics presently has a consensus rating of “Buy” and an average price target of $12.20.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Further Reading: How to execute a trade ex-dividend strategy?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.